Sanofi Website

Sanofi

ENXTPA-SAN

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Operating Revenues

36,126

36,041

37,761

42,997

43,070

44,092

Other Revenues, Total

1,505

1,328

1,414

2,392

2,963

2,988

Total Revenues

37,631

37,369

39,175

45,389

46,033

47,080

Total Revenues % Chg.

5.5%

-0.7%

4.8%

15.9%

1.4%

2.2%

Cost of Goods Sold, Total

11,976

12,106

12,251

13,692

14,216

14,704

Gross Profit

25,655

25,263

26,924

31,697

31,817

32,376

Selling General & Admin Expenses, Total

9,967

9,448

9,599

10,539

10,765

10,842

R&D Expenses

6,020

5,530

5,692

6,706

6,728

6,958

Amortization of Goodwill and Intangible Assets

2,146

1,681

1,580

1,827

2,172

2,198

Other Operating Expenses

720

1,025

1,488

1,587

2,950

3,883

Other Operating Expenses, Total

18,853

17,684

18,359

20,659

22,615

23,881

Operating Income

6,802

7,579

8,565

11,038

9,202

8,495

Interest Expense, Total

-544

-459

-362

-394

-527

-606

Interest And Investment Income

91

37

3

173

546

546

Net Interest Expenses

-453

-422

-359

-221

19

-60

Income (Loss) On Equity Invest.

255

359

39

68

-115

-76

Currency Exchange Gains (Loss)

1

-6

2

-4

-2

2

Other Non Operating Income (Expenses)

236

144

70

37

-665

-812

EBT, Excl. Unusual Items

6,841

7,654

8,317

10,918

8,439

7,549

Restructuring Charges

-1,088

-1,089

-820

-1,336

-1,490

-2,274

Merger & Related Restructuring Charges

—

—

—

-3

-53

-4

-3

-20

-34

Gain (Loss) On Sale Of Investments

—

—

—

7,388

3

1

-1

-1

Gain (Loss) On Sale Of Assets

—

296

443

418

655

688

664

Asset Writedown

-3,604

-330

-192

228

-896

-510

Legal Settlements

—

—

—

—

—

327

—

—

—

—

—

Other Unusual Items

238

124

115

27

318

184

EBT, Incl. Unusual Items

3,007

14,137

7,837

10,490

7,038

5,578

Income Tax Expense

121

1,807

1,558

2,006

1,602

1,335

Earnings From Continuing Operations

2,886

12,330

6,279

8,484

5,436

4,243

Earnings Of Discontinued Operations

-101

—

—

—

—

—

Minority Interest

-31

-36

-56

-113

-36

-27

Net Income

2,754

12,294

6,223

8,371

5,400

4,216

Net Income to Common Incl Extra Items

2,754

12,294

6,223

8,371

5,400

4,216

Net Income to Common Excl. Extra Items

2,855

12,294

6,223

8,371

5,400

4,216

Total Shares Outstanding

1,253.8

1,250.7

1,252.5

1,252.6

1,251.3

1,251

Weighted Avg. Shares Outstanding

1,249.9

1,253.6

1,252.5

1,251.9

1,251.7

1,251.5

Weighted Avg. Shares Outstanding Dil

1,257.1

1,260.1

1,257.9

1,256.9

1,256.4

1,256.1

EPS

2.2

9.8

5

6.7

4.3

3.4

EPS Diluted

2.2

9.8

5

6.7

4.3

3.4

EBITDA

10,113

10,466

11,251

14,062

12,520

11,754

Effective Tax Rate

4%

12.8%

19.9%

19.1%

22.8%

23.9%